Nebenwirkungen · Simulect
Simulect 20 mg powder and solvent for solution for injection or infusion Simulect 20 mg powder for solution for injection or infusion · Abschnitt 4.8 · PDF-Seite 6
HOS-089015 · Präparat HOS-083755
The incidence and causes of deaths following dual or triple therapy were similar in basiliximab (2.9%) and placebo groups (2.6%), with the most common cause of deaths in both treatment groups being infections (basiliximab = 1.3%, placebo = 1.4%). In a pooled analysis of two five-year extension studies the incidence and cause of death remained similar in both treatment groups, (basiliximab 15%, placebo 11%), the primary cause of death being cardiac-related disorders such as cardiac failure and myocardial infarction (basiliximab 5%, placebo 4%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-19T11:51:00Z · SHA-256 733fba3a740348b21107babe9d9387936dfd68357cde53822fb186eb4a9d7e0d · Passage 86a294738626fbf1e8d644e69cbf9c534efc62446ae49961b74590568f02f5ad · Zeichen 3234–3783 im Abschnitt